investor_presentation
Equifax
Loading viewer...
investor_presentation
Format: PDF investor_presentation
HLS Therapeutics presents its 2021 investor update highlighting Vascepa as an inflection point for growth. The company projects peak-year Vascepa royalty revenue of C$275-325M and C$100-130M in other revenue, with estimated market cap of C$540M. Key products include Clozaril, Trinomia, PERSERIS, and MyCare.
investor_presentation
23 Pages
investor_presentation
39 Pages
Novolipetsk Steel
Shapeways Q3 2023 Investor Presentation
investor_presentationinvestor_presentation
20 Pages
Shapeways Holdings, Inc.
investor_presentation
Equifax